AesMed at FUE ASIA SAARC Regional Workshop 2026: Advancing Hair follicular science and Regenerative Hair Care
From January 9 to 12, 2026, AesMed proudly participated as an exhibitor at the FUE ASIA SAARC Regional Workshop 2026, one of the world’s largest and most influential conferences dedicated to Hair follicular science, hair disorders, medical treatments, regenerative trichology, and hair transplantation.
Held in Hyderabad, India, this international workshop brought together leading hair transplant surgeons, dermatologists, researchers, and industry experts from across the SAARC region and beyond. For AesMed, the event represented an important opportunity to engage directly with the global medical hair-loss community and to share our latest scientific approach to alopecia care.
A Global Platform for Hair Restoration Innovation
The FUE ASIA SAARC Regional Workshop is widely recognized for its strong emphasis on hands-on education, evidence-based practice, and scientific exchange. The program featured expert lectures, interactive workshops, live surgical demonstrations, and in-depth discussions covering both foundational and advanced techniques in hair transplantation and regenerative trichology.
By participating in this highly respected forum, AesMed reaffirmed its commitment to staying closely aligned with clinical practice and emerging scientific trends in hair restoration.
Introducing CytoMesopecia – Cytokines Mesotherapy for Alopecia
At the core of AesMed’s presentation was CytoMesopecia – Cytokines Mesotherapy for Alopecia, an advanced treatment framework supported by the clinical application of AGF39, AesMed’s proprietary cytokine-based solution for hair loss care.
AGF39 has been introduced and actively utilized in hair-loss treatment hospitals and specialized clinics across Korea, Japan, China, and other Asian markets, where it has accumulated one of the largest volumes of clinical procedures among cytokine-based mesotherapy solutions. This extensive real-world use has contributed to a growing body of clinical experience and data, supporting its relevance in professional alopecia management.
Through CytoMesopecia, AGF39 is delivered via targeted mesotherapy to the scalp dermis, where hair follicles reside, with the aim of optimizing the follicular microenvironment, supporting anagen phase maintenance, and promoting regenerative signaling. The treatment concept reflects a shift from short-term symptom control toward biologically driven modulation and long-term follicular support.
At the AesMed booth, medical professionals showed strong interest in the clinical positioning of AGF39 – particularly its practical integration into daily clinical workflows, compatibility with combination therapies, and its proven track record in high-volume hair-loss treatment settings across Asia.
Meaningful Engagement With Global Professionals
Throughout the workshop, AesMed engaged in thoughtful conversations with clinicians and researchers from different regions, exchanging perspectives on clinical challenges, patient needs, and the future direction of hair-loss treatment.
These interactions reinforced the importance of collaboration between science, clinical practice, and industry – a principle that lies at the heart of AesMed’s philosophy.
Looking Ahead: Building the Future of Regenerative Trichology
AesMed’s participation in the FUE ASIA SAARC Regional Workshop 2026 is part of a broader commitment to global engagement and continuous learning. By actively participating in international scientific conferences, AesMed aims to contribute to the advancement of evidence-based, biologically driven alopecia care.
As the field of hair restoration continues to evolve, AesMed will remain focused on developing and sharing innovative solutions that support medical professionals and ultimately improve patient outcomes.
Learn more about AesMed: www.aesmed.co.kr
